Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030

All the vital news, analysis, and commentary curated by our industry experts.

$10995

Buy Report View Sample

Published: May 31, 2021 Report Code: GDHC221PIDR-ST

Report Overview
Key Players
Table of Contents
Table
Figures

Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease that causes progressive fibrosis of the skin and internal organs, as well as vascular dysfunction. The presentation of the disease is heterogeneous, both in the organ systems affected and the overall severity of symptoms. The most common complications of SSc include digital vasculopathy (Raynaud’s phenomenon and digital ulcers), skin fibrosis, lung fibrosis or interstitial lung disease (ILD), pulmonary arterial hypertension, gastrointestinal issues, arthritis, myopathy, and scleroderma renal crisis. As there are no systemic disease-modifying therapies currently available that significantly alter the course of the disease, the SSc treatment paradigm is to manage complications within individual organ systems as they occur.

GlobalData's report and forecast model focus specifically on the treatment of SSC-associated digital vasculopathy, skin fibrosis, and ILD. Most of the drugs used to treat these disease manifestations are decades-old generic agents that have been repurposed from other indications, including immunosuppressive agents (such as methotrexate, mycophenolate mofetil, and cyclophosphamide) and vasodilative cardiovascular drugs (such as calcium channel blockers, PDE5 inhibitors, and prostacyclin analogs). The vast majority of SSc therapies are used off-label. However, there has recently been a major shift in the SSc market landscape, and new players are beginning to enter the space.

GlobalData projects that the global SSc market, which comprises the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), will experience strong growth during the forecast period, at a Compound Annual Growth Rate (CAGR) of 14.0%, with sales growing from $498.0M in 2020 to $1.8B in 2030. Global growth in the SSc market will be driven by uptake of Boehringer Ingelheim’s (BI) recently launched Ofev (nintedanib) and Roche/Genentech’s Actemra/RoActemra (tocilizumab) for the treatment of SSc-associated ILD, along with the anticipated approval and launch of six pipeline therapies. This growth will be limited by sales erosion from generic nintedanib and biosimilars.

In this report, GlobalData focuses its market forecast analysis on six Phase III and late Phase II products expected to be licensed for SSc between 2020 and 2030. These include four small molecule drugs—Civi BioPharma/Eicos Sciences’ IV Civi-030 (iloprost), Horizon Therapeutics’ HZN-825, Kadmon Corporation’s belumosudil mesylate, and Mitsubishi Tanabe Pharma’s dersimelagon—and two monoclonal antibodies currently marketed for the treatment of PSO and PsA—Kyowa Kirin’s Lumicef (brodalumab) and J&J’s Tremfya (guselkumab).

Although key opinion leaders (KOLs) interviewed by GlobalData were pleased to see such an innovative late-stage pipeline for SSc, they did highlight major, lingering unmet needs in the field. These include needs for the development of disease-modifying and anti-fibrotic therapies, earlier diagnosis and treatment, and improved prognostic biomarkers. KOLs were optimistic about the future of SSc but believed there was significant work left to be done in this space.

KEY QUESTIONS ANSWERED

For the first time ever, treatment options for patients with SSc are beginning to expand.
– What impact will the recently launched drugs, Ofev and Actemra/RoActemra, have on the treatment of SSc throughout the 7MM?
– What pipeline agents are currently in late-stage clinical development, and which are the most promising?

Growing interest in SSc by the pharmaceutical industry is transforming research and development practices in the field.
– What are the main R&D trends in the SSc market and which companies are leading the way?
– How is clinical trial design for SSc changing and in what ways does it differ depending on disease manifestation?

KOLs interviewed by GlobalData have indicated that there are still many remaining unmet needs within the SSc indication.
– What are the main unmet needs in the SSc market?
– How can the pharmaceutical industry address these needs?
– To what degree will the therapies under development fulfill these unmet needs?

Scope

Overview of SSc including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline SSc therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting SSc therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global SSc therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The greatest drivers of growth in the global SSc market will be the recent launches of Ofev and Actemra/RoActemra for the treatment of ILD associated with SSc, the anticipated approval and launch of six pipeline therapies, a steadily climbing diagnosed prevalence rate, and a growing overall treatment rate due to growing access to new therapies.

The main barriers to growth in the SSc market will be significant market share erosion from biosimilars and nintedanib generics as well as a historical treatment paradigm that focuses on the off-label use of inexpensive generic products.

KOLs expressed enthusiasm for the six pipeline agents in development. Of these agents, KOLs were most interested in Civi Biopharma/Eicos Sciences’ Civi-030, Horizon Therapeutics’ HZN-825, and Kadmon Corporation’s belumosudil mesylate.

The most important unmet needs in SSc are those for the development of disease-modifying and anti-fibrotic therapies, earlier diagnosis and treatment, and improved prognostic biomarkers.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global SSc therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SSc market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global SSc therapeutics market from 2020-2030.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie Inc
Boehringer Ingelheim
Bristol-Myers Squibb Co
Chugai Pharmaceutical Co Ltd
Civi Biopharma Inc
Corbus Pharmaceuticals Inc
Eicos Sciences Inc
F. Hoffmann-La Roche Ltd
Genentech Inc
Horizon Therapeutics Plc
Janssen
Johnson & Johnson
Kadmon Holdings Inc
Kyowa Kirin Co Ltd
Mitsubishi Tanabe Pharma Co
Ono Pharmaceutical Co

| About GlobalData

1 Systemic Sclerosis: Executive Summary

1.1 New Drug Approvals Expected to Drive Strong Growth in SSc

1.2 Current SSc Market Dynamics Reflect a Blend of New and Old R&D Strategies

1.3 While Outlook in SSc Improves, Opportunities Remains to Improve Patient Outcomes

1.4 SSc Pipeline Targets the Skin, Lungs, and Vasculature with New MOAs

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Disease Classification

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 7MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc – 7MM

4.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc by Subtype

4.4.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

4.4.6 Diagnosed Prevalent Cases of by other Internal Organ Involvement and Comorbidities

4.5 Epidemiological Forecast for Systemic Sclerosis (2020-2030)

4.5.1 Diagnosed Prevalent Cases of SSc

4.5.2 Age-Specific Diagnosed Prevalent Cases of SSc

4.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc

4.5.4 Diagnosed Prevalent Cases of SSc by Subtype

4.5.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

4.5.6 Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement

4.5.7 Diagnosed Prevalent Cases of SSc with Comorbid Malignancy

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis

5.2 Treatment

5.2.1 Digital Vasculopathy

5.2.2 Skin and Lung Fibrosis

5.2.3 Other Organ Involvement

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of Disease-Modifying Therapies

7.3 Lack of Anti-Fibrotic Drugs

7.4 Earlier Referral and Treatment

7.5 Improved Prognostic Biomarkers

8 R&D Strategies

8.1 Overview

8.1.1 Repurposing of Drugs Used for Autoimmune and Cardiovascular Diseases

8.1.2 Big Pharma Forges Ahead in SSc-ILD Approvals

8.1.3 New Mechanisms of Action for Early Dc-SSc

8.2 Clinical Trial Design

8.2.1 Early Dc-SSc

8.2.2 SSc-ILD

8.2.3 Digital Vasculopathy

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Civi-030

9.2.2 HZN-825

9.2.3 Belumosudil Mesylate

9.2.4 Dersimelagon

9.2.5 Lumicef and Tremfya

9.3 Other Drugs of Note

9.3.1 Lenabasum

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Skin Fibrosis

10.2.2 Lung Fibrosis

10.2.3 Digital Vasculopathy

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.4.2 Payors

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Epidemiology Reviewers

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: SSc Key Metrics in the 7MM

Table 2: Classification Groups for SSc

Table 3: Risk Factors and Comorbidities for SSc

Table 4: Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement

Table 5: 2013 ACR/EULAR Criteria for the Classification of SSc

Table 6: Frequency and Clinical Correlation of Select SSc-associated Nuclear Autoantibodies

Table 7: Treatment Guidelines for SSc

Table 8: Comparison of Provisional ACR-CRISS and Revised ACR-CRISS

Table 9: Key Deals in SSc Market, 2016-2021

Table 10: SSc Market – Global Drivers and Barriers, 2020-2030

Table 11: Key Events Impacting Sales for SSc in the US, 2020-2030

Table 12: SSc Market – Drivers and Barriers in the US, 2020-2030

Table 13: Key Events Impacting Sales for SSc in the 5EU, 2020-2030

Table 14: SSc Market – Drivers and Barriers in the 5EU, 2020-2030

Table 15: Key Events Impacting Sales for SSc in Japan, 2020-2030

Table 16: SSc Market – Drivers and Barriers in Japan, 2020-2030

Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global (7MM) Sales Forecast by Country for SSc in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in SSc During the Forecast Period

Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Skin Fibrosis, MMF and MTX

Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Lung Fibrosis, MMF and Ofev

Figure 5: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for SSc-Associated Digital Vasculopathy, Generic Epoprostenol

Figure 6: SSc Pathophysiology and Associated Therapeutic Mechanisms

Figure 7: 7MM, Diagnosed Prevalence of SSc, Men and Women, %, Ages ≥18 Years, 2020

Figure 8: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of SSc

Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Subtype

Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement – ILD, PAH, and Kidney Disease

Figure 12: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement – Cardiac Involvement, Gastrointestinal Involvement, Musculoskeletal Involvement, and Neuromuscular Involvement; and Comorbidity – Malignancy

Figure 13: 7MM, Diagnosed Prevalent Cases of SSc, N, Both Sexes, Ages ≥18 Years, 2020

Figure 14: 7MM, Diagnosed Prevalent Cases of SSc by Age, N, Both Sexes, 2020

Figure 15: 7MM, Diagnosed Prevalent Cases of SSc by Sex, N, Ages ≥18 Years, 2020

Figure 16: 7MM, Diagnosed Prevalent Cases of SSc by Subtype, N, Both Sexes, Ages ≥18 Years, 2020

Figure 17: 7MM, Diagnosed Prevalent Cases of SSc by Digital Vasculopathy, N, Both Sexes, Ages ≥18 Years, 2020

Figure 18: 7MM, Diagnosed Prevalent Cases of SSc with Comorbid Malignancy, N, Both Sexes, Ages ≥18 Years, 2020

Figure 19: General Treatment Algorithm for SSc-Associated Digital Vasculopathy, 2021

Figure 20: General Treatment Algorithm for SSc-Associated Skin and Lung Fibrosis, 2021

Figure 21: Unmet Needs and Opportunities in SSc

Figure 22: Overview of the Development Pipeline in SSc

Figure 23: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects Be Licensed for SSc in the 7MM During the Forecast Period

Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Skin Fibrosis, MMF and MTX

Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOCs for SSc-Associated Lung Fibrosis, MMF and Ofev

Figure 26: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for SSc-Associated Digital Vasculopathy, Generic Epoprostenol

Figure 27: Analysis of the Company Portfolio Gap in SSc During the Forecast Period

Figure 28: Global (7MM) Sales Forecast by Country for SSc in 2020 and 2030

Figure 29: Global (7MM) Sales Forecast by Drug Class for SSc in 2020 and 2030

Figure 30: Sales Forecast by Drug Class for SSc in the US in 2020 and 2030

Figure 31: Sales Forecast by Drug Class for SSc in the 5EU in 2020 and 2030

Figure 32: Sales Forecast by Drug Class for SSc in Japan in 2020 and 2030

Frequently asked questions

Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030 standard reports

Currency USD

Single User

$10,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Immunology reports

Pharmaceuticals

New

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…

Pharmaceuticals

New

Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…

Pharmaceuticals

New

Generic Drugs - Physician Perspective - Thematic Intelligence

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030 in real time.

Access a live Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030

Scope

Key Highlights

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports